Recruitment Status

Recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 6:19 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

22012

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Crohn Disease
Interventions: Icotrokinra, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,092 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 64
States / cities: Chandler, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 51 more

Conditions: Multiple Sclerosis (MS) - Relapsing-remitting, Upper Extremity Dysfunction
Interventions: wearable focal vibration therapy; Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Gainesville, Florida

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Interventions: TAK-411; Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 15
States / cities: La Jolla, California • San Francisco, California • Washington D.C., District of Columbia + 12 more

Conditions: Pediatric Osteosarcoma
Interventions: Cyclophosphamide, Fludarabine, Mesna, Apheresis, SJCARB7H3_41BBL infusion; Drug · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: HIV -1 Infection
Interventions: Every 4-week long-acting injectable cabotegravir and rilpivirine; Drug
Lead sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 10
States / cities: La Jolla, California • Los Angeles, California • Aurora, Colorado + 7 more

Conditions: Alzheimer's Disease
Interventions: Psilocybin, Cognitive Training; Drug · Other
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 65 Years to 120 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Colorectal Cancer, Advanced/Metastatic Solid Tumor, Solid Tumor (Phase I), EPCAM, Colon Cancer
Interventions: LTZ-232; Drug
Lead sponsor: LTZ Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Interventions: Biospecimen Collection, Cyclophosphamide, Doxorubicin, Durvalumab, Genetic Testing, Mammography, Paclitaxel, Quality-of-Life Assessment; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 3,680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 561
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 431 more

Conditions: Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Precancerous Condition
Interventions: immunohistochemistry staining method, laboratory biomarker analysis, sputum cytology, biopsy; Other · Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years to 90 Years
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: NSCLC Stage II, NSCLC, Stage III
Interventions: Precision Exercise Regimen for Cancer Care (PERCC); Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Galveston, Texas • Salt Lake City, Utah

Conditions: Narcolepsy Type 1, Narcolepsy Type 2
Interventions: cleminorexton, Placebo; Drug
Lead sponsor: Centessa Pharmaceuticals (UK) Limited; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 26
States / cities: Birmingham, Alabama • Colorado Springs, Colorado • Brandon, Florida + 20 more

Conditions: Sickle Cell Disease
Interventions: Anumigilimab, Placebo; Biological · Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 14
States / cities: Little Rock, Arkansas • Orange, California • Hollywood, Florida + 11 more

Recruiting clinical trials

Filter and sort this status page

Live official records

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study

A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma

Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy

Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin

This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers

PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) Study

A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence

Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)